Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Y. Nakamura (Matsusaka City, Mie Prefecture, Japan), O. Hataji (Matsusaka City, Mie Prefecture, Japan), K. Furuhashi (Matsusaka City, Mie Prefecture, Japan), Y. Suzuki (Matsusaka City, Mie Prefecture, Japan), T. Sakaguchi (Matsusaka City, Mie Prefecture, Japan), K. Ito (Matsusaka City, Mie Prefecture, Japan), K. Fujiwara (Matsusaka City, Mie Prefecture, Japan), Y. Nishii (Matsusaka City, Mie Prefecture, Japan), O. Taguchi (Matsusaka City, Mie Prefecture, Japan), E. Gabazza (Tsu, Japan). Clinical efficacy of 1st line EGFR-TKIs for NSCLC habouring EGFR mutation with high PD-L1 expression; A single-centered retrospective study. 1744

Member's Comments

No comment yet.

Related content which might interest you: Retrospective study of treatment outcomes according to exon difference with EGFR mutations in non-small cell lung cancer patient in Korea Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012 Outcomes of NSCLC patients with positive EGFR mutation Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 Positive PD-L1 expression is associated with unfavorable clinical outcome in EGFR-mutated lung adenocarcinomas treated with EGFR-TKIs Source: International Congress 2019 – Treatment of lung cancer Year: 2019 Nationwide real-world cohort study of first line TKI treatment in epidermal growth factor receptor mutated non-small cell lung cancer. Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020 Homozygous deletion of PTEN and poor outcomes in EGFR mutant NSCLC patients with gefitinib therapy Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Late Breaking Abstract - Randomized phase III study of erlotinib compared to intercalated erlotinib with cisplatin and pemetrexed as first-line therapy for advanced EGFR mutated non-small cell lung cancer, the NVALT 17 study. Source: Virtual Congress 2021 – New clinical and biological developments in lung cancer Year: 2021 The selective EGFR tyrosine-kinase inhibitor erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) – a single institution experience of TRUST – a worldwide open label non randomized phase IV trial Source: Annual Congress 2007 - Therapy of lung cancer Year: 2007 Pembrolizumab versus nivolumab as second and further line treatment in non-small cell lung cancer; a retrospective single-centre study Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020 Survival analysis of advanced NSCLC patients harboring EGFR mutations with zoledronate or denosumab Source: International Congress 2017 – Clinical research in lung cancer: new valuable results on lung cancer detection, prognostic biomarkers, and tyrosine kinase inhibitors Year: 2017 Survival prognosis and target therapy best response in adenocarcinoma lung cancer pts with mutation EGFR gene Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 A prospective phase II study of gefitinib for chemo-naïve patients with advanced non-small cell lung cancer with epidermal growth factor receptor gene mutations Source: Annual Congress 2006 - Lung cancer treatment Year: 2006 ERCC1 and MDR1 expression and polymorphism frequency related to clinical outcome and chemotherapy response in a Brazilian sample of NSCLC patients Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Potential therapeutic significance of CIK cells in gefitinib resistant NSCLC with EGFR mutations Source: Annual Congress 2011 - Progress in pathology of lung cancer Year: 2011 LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) vs gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung Source: Annual Congress 2013 –Advances in the therapy of lung cancer Year: 2013 Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3 Source: Eur Respir J 2011; 39: 172-179 Year: 2012 Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3 Source: Eur Respir J 2012; 39: 172-179 Year: 2012 Pemetrexed in the first line treatment in non-small cell lung cancer (NSCLC): A multicentre prospective analysis of data from clinical practise of Czech Republic Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Dynamic monitoring of EGFR mutations in circulating tumor DNA for early detection of drug resistance in NSCLC patients on EGFR-TKI therapy Source: International Congress 2019 – Diagnostic procedures and biology of lung cancer Year: 2019 Clinical and molecular features of V600E and non-V600E BRAF mutations in NSCLC – a retrospective monocentric observational study Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020 Efficacy of Afatinib, Erlotinib, and Gefitinib on epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients with brain metastasis: a network meta-analysis Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018